Learn from German Accelerator’s experienced regulatory mentor, Greg Dombal, how to navigate the impact of COVID-19 on clinical trials and FDA approval timelines and processes. The German Accelerator team will provide answers on how startups can mitigate their risks around trial integrity, safety of trial participants, and other relevant issues. During the session, opportunities for startups will be highlighted, such as the FDA’s recently announced special emergency program for possible therapies, the Coronavirus Treatment Accelerator Program (CTAP). This online seminar will be moderated by Marc Filerman, CEO German Accelerator Life Sciences. 

Mehr Informationen